Search research articles
Contact Us
Filters
Showing results (331-340 of 349) with videos related to
Page
of 35
Sort By:
Journal of Medicinal Chemistry
|
July 21, 1998
Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements
S E Webber, K Okano, T L Little, et al.
American Journal of Medical Genetics. Part A
|
November 26, 2009
Genome-wide linkage scan of nonsyndromic orofacial clefting in 91 families of central European origin
Elisabeth Mangold, Heiko Reutter, Stefanie Birnbaum, et al.
Nature Medicine
|
January 16, 2019
Translation control of the immune checkpoint in cancer and its therapeutic targeting
Yichen Xu, Mauro Poggio, Hyun Yong Jin, et al.
Birth Defects Research. Part A, Clinical and Molecular Teratology
|
October 20, 2012
Resequencing of VAX1 in patients with nonsyndromic cleft lip with or without cleft palate
Entessar Nasser, Elisabeth Mangold, Daniela C Tradowsky, et al.
Journal of Medicinal Chemistry
|
May 30, 2020
Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase
Justin T Ernst, Peggy A Thompson, Christian Nilewski, et al.
European Journal of Oral Sciences
|
February 4, 2010
IRF6 gene variants in Central European patients with non-syndromic cleft lip with or without cleft palate
Stefanie Birnbaum, Kerstin U Ludwig, Heiko Reutter, et al.
Journal of Medicinal Chemistry
|
May 3, 2002
Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C protease
Theodore O Johnson, Ye Hua, Hiep T Luu, et al.
Journal of Medicinal Chemistry
|
December 16, 1997
Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease
S W Kaldor, V J Kalish, J F Davies, et al.
Molecular Cancer Therapeutics
|
October 10, 2020
Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A
Peggy A Thompson, Boreth Eam, Nathan P Young, et al.
BMC Cancer
|
November 1, 2019
A matched-pair analysis on survival and response rates between German and non-German cancer patients treated at a Comprehensive Cancer Center
Marie K Budde, Walther Kuhn, Mignon-Denise Keyver-Paik, et al.
Page
of 35
Search research articles
Search
Showing results (331-340 of 349) with videos related to
Sort By:
Page
of 35
Journal of Medicinal Chemistry
|
July 21, 1998
Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements
S E Webber, K Okano, T L Little, et al.
American Journal of Medical Genetics. Part A
|
November 26, 2009
Genome-wide linkage scan of nonsyndromic orofacial clefting in 91 families of central European origin
Elisabeth Mangold, Heiko Reutter, Stefanie Birnbaum, et al.
Nature Medicine
|
January 16, 2019
Translation control of the immune checkpoint in cancer and its therapeutic targeting
Yichen Xu, Mauro Poggio, Hyun Yong Jin, et al.
Birth Defects Research. Part A, Clinical and Molecular Teratology
|
October 20, 2012
Resequencing of VAX1 in patients with nonsyndromic cleft lip with or without cleft palate
Entessar Nasser, Elisabeth Mangold, Daniela C Tradowsky, et al.
Journal of Medicinal Chemistry
|
May 30, 2020
Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase
Justin T Ernst, Peggy A Thompson, Christian Nilewski, et al.
European Journal of Oral Sciences
|
February 4, 2010
IRF6 gene variants in Central European patients with non-syndromic cleft lip with or without cleft palate
Stefanie Birnbaum, Kerstin U Ludwig, Heiko Reutter, et al.
Journal of Medicinal Chemistry
|
May 3, 2002
Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C protease
Theodore O Johnson, Ye Hua, Hiep T Luu, et al.
Journal of Medicinal Chemistry
|
December 16, 1997
Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease
S W Kaldor, V J Kalish, J F Davies, et al.
Molecular Cancer Therapeutics
|
October 10, 2020
Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A
Peggy A Thompson, Boreth Eam, Nathan P Young, et al.
BMC Cancer
|
November 1, 2019
A matched-pair analysis on survival and response rates between German and non-German cancer patients treated at a Comprehensive Cancer Center
Marie K Budde, Walther Kuhn, Mignon-Denise Keyver-Paik, et al.
Page
of 35